Xanthoma E75.5

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 22.10.2022

Dieser Artikel auf Deutsch


Xanthom; Yellow Node

This section has been translated automatically.

Macular, papular or nodular, skin-colored, yellow, brown, red or brown-red neoplasms caused by local storage of serum lipoproteins in macrophages of the skin and/or subcutaneous tissue, sometimes with underlying elevation of serum lipoproteins, but sometimes also occurring normlipemically. There are close pathogenetic relationships or overlaps to/with the (normlipemic) non-Langerhans cell histiocytoses (see under xanthogranulomas).

This section has been translated automatically.

Classification is based on clinical and laboratory criteria.

Clinical differentiation:

  • plane xanthomas (e.g. xanthelasma)
  • eruptive xanthomas (disseminated nodules)
  • tendon xanthomas (deep-seated soft nodules)
  • tuberous xanthomas.

Laboratory chemistry distinguishes:

This section has been translated automatically.

This section has been translated automatically.

Predominantly fat-storing macrophages (foam cells) and possibly foreign body giant cells and Toutonian giant cells. Later fibrosis, cholesterol granulomas.

This section has been translated automatically.

S. under the listed dermatoses.

This section has been translated automatically.

  1. Bayer-Garner IB et al (2003) The spectrum of cutaneous disease in multiple myeloma. J Am Acad Dermatol 48: 497-507.
  2. Bel S et al (2001) Cerebrotendinous xanthomatosis. J Am Acad Dermatol 45: 292-295.
  3. Broeshart JH (2003) Normolipemic plane xanthoma associated with adenocarcinoma and severe itch. J Am Acad Dermatol 49: 119-122.
  4. Caputo R et al (2002) Progressive histiocytosis: description of a case of slow-course non-Langerhans cell histiocytosis. Dermatology 205: 293-297
  5. Chang HY (2003) Eruptive xanthomas associated with olanzapine use. Arch Dermatol 139: 1045-1048
  6. Cohen YK et al (2015) Diffuse normolipemic plane xanthoma associated with monoclonal gammopathy. Dermatol Pract Concept 5:65-67.
  7. Heller R et al (2002) Cerebrotendinous xanthomatosis, a treatable metabolic disorder. Neurologist 73: 1160-1166.
  8. Hirata Y et al (2002) Low density lipoprotein oxidized in xanthoma tissue induces the formation and infiltration of foam cells. J Dermatol Sci 30: 248-255.
  9. Koyama S et al (2021) Cerebrotendinous xanthomatosis: molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments. J Atheroscler Thromb 28: 905-925.
  10. Krishna VC et al (2016) Xanthoma disseminatum with extensive coebnerization associated with familial hypertriglyceridemia C. JAAD 2: 253-256.
  11. Muscardin LM et al (2003) Necrobiotic xanthogranuloma without periorbital lesions and without paraproteinaemia. J Eur Acad Dermatol Venereol 17: 233-235.
  12. Naik NS (2001) Eruptive xanthomas. Dermatol Online J 7: 11
  13. Watermann DF et al (2001) Skin manifestations of Erdheim-Chester disease. Case report and review of the literature. Dermatol 52: 510-517
  14. Ochsendorf F (2020) Manifestations of internal diseases on the skin. Consilium Dermatologie live 2: 24-29


Please ask your physician for a reliable diagnosis. This website is only meant as a reference.


Last updated on: 22.10.2022